{"title":"MHRA 发布氟喹诺酮类药物安全性的进一步更新信息","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000021","DOIUrl":null,"url":null,"abstract":"### Key learning points The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1 In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"65 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MHRA issues further update on fluoroquinolone safety\",\"authors\":\"BMJ Publishing Group Ltd\",\"doi\":\"10.1136/dtb.2024.000021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"### Key learning points The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1 In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …\",\"PeriodicalId\":11277,\"journal\":{\"name\":\"Drug and Therapeutics Bulletin\",\"volume\":\"65 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and Therapeutics Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/dtb.2024.000021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and Therapeutics Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/dtb.2024.000021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
MHRA issues further update on fluoroquinolone safety
### Key learning points The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1 In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
